Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab and Relatlimab in Stage I-III Merkel Cell Carcinoma
NCT06151236Phase 2Recruiting
- Sponsor
- Melanoma Institute Australia
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of relatlimab in Merkel cell carcinoma (MCC), sponsored by Melanoma Institute Australia. Primary endpoint: Pathological Complete Response Rate at 6 weeks. Started Mar 2024; status: recruiting.
02
Drugs
relatlimab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT06151236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06151236.